Brief: Lumos Pharma Appoints Mark Bach to Clinical Scientific Advisory Board
26/07/2021 21:35
July 26 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA APPOINTS PEDIATRIC ENDOCRINOLOGIST
EXPERIENCED IN
CLINICAL RESEARCH AND PHARMACEUTICAL DEVELOPMENT, MARK BACH,
M.D., PH.D., TO CLINICAL SCIENTIFIC ADVISORY BOARD
Source text for Eikon: ID:nGNX1z8j1l
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)